Latest news with #VBP
Business Times
a day ago
- Business
- Business Times
Hong Kong-listed China Medical System seeks secondary listing on SGX
[SINGAPORE] Hong Kong-listed China Medical System (CMS) is seeking a secondary listing on the mainboard of the Singapore Exchange (SGX) in July this year. CMS is a specialty pharma with a focus on sales and marketing in China, with capabilities across the full lifecycle of drug development, from identifying clinical needs to research and development (R&D) regulatory approval, and commercialisation. It has been listed on the Stock Exchange of Hong Kong since 2010. The pharmaceutical company expects the secondary listing will help it deepen its presence in South-east Asia and 'tap into a new and sophisticated investor base in Singapore'. CMS said it is looking to replicate its success in South-east Asia – building on the proven track record attained in China's pharmaceutical industry. 'This region, with a population of nearly 700 million, is experiencing surging pharmaceutical demand due to rapid economic growth, the rise of the middle class, ageing population, and the increasing burden of non-infectious diseases,' it said. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Its financial performance in 2023 and 2024 were hit by China's volume-based procurement (VBP) policy – three of its products were included in the VBP list. This policy aims to lower the prices of drugs with generic competition, by guaranteeing certain procurement volumes from public hospitals at significantly reduced prices through a bidding process. But CMS had a top-line rebound in H2 2024, driven by progress in commercialising innovative drugs and the continued growth of non-VBP exclusive products. The company moved towards innovative drugs, given that they typically enjoy a pricing advantage due to their exclusiveness, novelty and quality, and are supported by favourable government policies. It expects growth momentum will accelerate on the back of the replenishment of its pipeline of innovative drugs to about 40 products as at Dec 31, 2024. It noted four key platforms to scale its pharmaceutical ecosystem across Asia-Pacific. CMS R&D is involved in drug discovery and development targeting global markets, while PharmaGend is a development and manufacturing platform for regional manufacturing and supply. It also has Rxilient Health, a Singapore-headquartered entity focused on registration and commercialisation in South-east Asia and a Singapore venture arm, which makes strategic investments to support regional pharma innovation. In a statement on Jun 24, CMS said the proposed listing will not involve issuance of new shares, and the shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter. Singapore is its regional headquarters for its South-east Asia and Middle East business, the company said. The announcement follows the news of several new listings on SGX – software services provider Info-Tech Systems, a data centre real estate investment trust (Reit) by Japanese telco Nippon Telegraph and Telephone (NTT), and a spin-off of mainboard-listed construction company Lum Chang Holdings' interior fit-out business. Info-Tech Systems, whose shares are expected to begin trading on Jul 4, is the first SGX mainboard listing in two years. NTT DC Reit, which will have a portfolio of six of NTT's data centre assets, will likely be the largest Singapore Reit listing in a decade. Meanwhile, interior fit-out business Lum Chang Creations is looking to list on the Catalist board.
Globe and Mail
2 days ago
- Business
- Globe and Mail
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
Johnson & Johnson JNJ is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J's medical devices segment, called MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues. Sales in the MedTech segment rose 4.1% on an operational basis in the first quarter of 2025, driven by new product uptake and commercial execution, and contributions from the recent acquisitions of Shockwave and Abiomed. However, sales in J&J's MedTech business continue to face headwinds in the Asia Pacific, particularly in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. VBP is a government-driven cost-containment effort in China. In the MedTech segment, recent acquisitions of Shockwave and Abiomed, as well as continued uptake of its new products, are likely to drive growth in 2025. However, J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses, such as PFA ablation catheters in U.S. electrophysiology. JNJ expects continued impacts from VBP issues in China in 2025 as VBP expands across provinces and products. Nonetheless, sales are expected to be higher in the second half of 2025 than in the first half as the business moves past tougher first-quarter comps and new products gain momentum throughout 2025. However, tariff-related costs are expected to hurt profits in the MedTech segment J&J's Key Competitors in the Medical Devices Market J&J's MedTech unit faces strong competition from several major players in the medical device industry like Medtronic MDT, Abbott, Stryker SYK and Boston Scientific BSX. While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker Corporation is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics, and diabetes care. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 7.1% in the year-to-date period against a 0.4% decline of the industry. From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.12 forward earnings, lower than 14.92 for the industry. The stock is also trading below its five-year mean of 15.74. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.60 per share over the past 60 days, while that for 2026 has declined from $11.00 to $10.98 over the same timeframe. J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report
Yahoo
11-06-2025
- Business
- Yahoo
Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions
Tandem Diabetes Care, Inc. recently announced a significant collaboration with Abbott Laboratories to integrate Abbott's upcoming dual glucose-ketone sensor with Tandem's insulin delivery systems. This and other collaborations, such as the agreement with Sequel Med Tech, align with Abbott's strategic focus on enhancing diabetes care. Abbott's shares rose 3% over the last quarter, aligning closely with broader market trends, which advanced 13% over the past year. The company's robust product approvals and partnerships, alongside positive market sentiment, likely reinforced investor confidence in Abbott's growth trajectory amid generally favorable market conditions. You should learn about the 1 possible red flag we've spotted with Abbott Laboratories. Find companies with promising cash flow potential yet trading below their fair value. The recent collaboration between Tandem Diabetes Care, Inc. and Abbott Laboratories to integrate Abbott's dual glucose-ketone sensor has the potential to enhance Abbott's market positioning in diabetes care. This partnership, along with other strategic agreements, could support revenue growth in Abbott's Diabetes Care segment, though challenges such as tariffs and VBP program impacts in China remain. Abbott's five-year total return, including share price and dividends, stands at 63.31%, showcasing strong longer-term performance, despite some earnings forecast pressure. In the past year, Abbott's shares have risen above the US Medical Equipment industry, which saw a return of 8.2%. This outperformance over a shorter time horizon indicates that investor confidence remains buoyant. However, the expectation of declining earnings over the next three years, with a 10.1% decrease per year, highlights forecast challenges. This contrasts with a forecasted revenue growth of 6.9% annually, which is slower than the broader US market growth rate of 8.6% per year. The current share price of US$133.06 reflects a modest 5.2% discount to the consensus analyst price target of US$140.41, suggesting a perception of fair valuation compared to expected earnings growth and projected revenue increases. Insights from our recent valuation report point to the potential undervaluation of Abbott Laboratories shares in the market. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New Straits Times
03-06-2025
- Business
- New Straits Times
Negri Sembilan, a major growth frontier for SD Property
KUALA LUMPUR: Negri Sembilan has emerged as a key growth frontier for some property developers particularly Sime Darby Property Bhd (SD Property). SD Property plays an instrumental role as one of the lead developers of the Malaysia Vision Valley 2.0 (MVV2.0) development corridor. MVV2.0 is a catalytic development initiative aimed at unlocking the economic potential of Negri Sembilan. As part of the National Physical Plan, MVV2.0 is intended to transform the southern corridor of the Klang Valley into a new growth frontier, leveraging strategic connectivity and proximity to Greater Kuala Lumpur. SD Property contributes to the activation of this corridor by unlocking its sizeable landbank in Nilai and Labu. Currently, SD Property holds about 4,000 acres of remaining land within MVV2.0, with an estimated remaining gross development value of RM16 billion. TA Securities said SD Property's management sees Negri Sembilan as a fast-emerging hotspot, offering industrial land at significantly more competitive pricing, about half the cost of similar offerings in Selangor while enjoying superior accessibility. This view is increasingly reflected in the group's sales composition, as Negri Sembilan accounted for 20 per cent of its total property sales in the quarter, up markedly from an average of just five per cent in FY24. The strong demand for units at Hamilton Nilai City and the positive initial response to Vision Business Park (VBP) highlight the state's growing importance as a strategic industrial destination. VBP, a 760-acre integrated industrial and commercial estate located within MVV2.0, is a key project for the property developer. Launched in April, VBP boasts an estimated gross development value of RM2.4 billion. It is situated near key infrastructure nodes including KLIA, KLIA2, the Nilai Inland Port and the North-South Expressway. The project is designed to attract logistics operators, light manufacturers, and technology-driven businesses, with product offerings ranging from ready-built factories and industrial plots to R&D facilities and commercial shop offices.
Yahoo
28-05-2025
- Business
- Yahoo
Abbott Laboratories (NYSE:ABT) Gains FDA Nod For Tendyne Mitral Valve System
Abbott Laboratories recently received FDA approval for its Tendyne™ TMVR system, a significant milestone enhancing its cardiovascular product portfolio. Over the past month, Abbott's stock price moved up by about 3%, which aligns with broader market trends, suggesting that its advancements may have supported this momentum. Alongside this, updates on partnerships and product innovations, such as integrating glucose monitoring data with Epic's health records and collaborating with MotoAmerica for brain injury assessments, likely added positive sentiment towards the company's robust and diversified healthcare offerings amidst a relatively flat market. We've spotted 1 warning sign for Abbott Laboratories you should be aware of. These 17 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. Abbott Laboratories' recent FDA approval for the Tendyne™ TMVR system could support its cardiovascular offerings and potentially bolster the company's financial outlook amid challenges like tariffs in 2025 and VBP programs in China. The share price's 3% rise over the past month, although modest, juxtaposed with prolonged financial pressures could signal mixed market sentiments. This aligns closely with the analyst price target of $140.41 in light of the current share price of US$133.06, highlighting cautious investor outlook amidst macroeconomic uncertainties. Over a five-year period ending May 2025, Abbott's total shareholder return, including dividends, hit 56.83%, marking a substantial increase. This contrasts with a return of 11.3% exceeding the US market in the past year alone. Within the US Medical Equipment industry, Abbott also performed better, surpassing the industry's 9.7% return over the same year span. However, earnings forecasts reflect challenges, with projections indicating a 10.1% annual decline over the next three years, raising questions about sustaining the past momentum. The recent developments involving FDA product approvals and partnerships with Epic and MotoAmerica may prompt revised revenue and earnings forecasts. These innovations could act as catalysts for future growth, yet significant investments required might compress margins short-term. As the projected returns align closely with current market valuations, investors may anticipate marginal increases as indicated by the consensus price target. As Abbott continues its diversification and global expansion efforts, understanding its financial dynamics becomes crucial for evaluating future potential returns. Evaluate Abbott Laboratories' prospects by accessing our earnings growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
